All In Biotech

Drug Trial Radar · NCT01193244

Study Comparing Orteronel Plus Prednisone in Participants With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer

A Phase 3, Randomized, Double-Blind, Multicenter Trial Comparing Orteronel Plus Prednisone With Placebo Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer

Last checked: Nov 19, 2026Latest source record: May 17, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,560 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,560

Actual

Start

Oct 1, 2010

Primary completion

Jan 1, 2014

Study completion Apr 7, 2016

Sponsor

Lead sponsor
Millennium Pharmaceuticals, Inc.Takeda (TAK)
Sponsor type
Industry
First posted
Sep 1, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a randomized, double-blind, multicenter, phase 3 study evaluating orteronel (TAK-700) plus prednisone compared with placebo plus prednisone in the treatment of men with progressive, chemotherapy-naive, metastatic, castration-resistant prostate cancer (mCRPC)

Conditions

  • Prostate Cancer

Interventions

  • OrteronelDrug

    Orteronel will be administered orally twice a day continuously throughout the study. Patients will also receive concomitant gonadotropin-releasing hormone (GnRH) analogue therapy unless they have previously undergone orchiectomy and have a testosterone concentration of \<50 ng/dL.

  • PlaceboDrug

    Placebo will be administered orally twice a day continuously throughout the study. Additionally, all patients will receive concomitant gonadotropin-releasing hormone (GnRH) analogue therapy unless they have previously undergone orchiectomy and a testosterone concentration of \<50 ng/dL.

  • PrednisoneDrug

    Prednisone will be administered orally twice a day continuously throughout the study. Patients will also receive concomitant gonadotropin-releasing hormone (GnRH) analogue therapy unless they have previously undergone orchiectomy and have a testosterone concentration of \<50 ng/dL.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Radiographic Progression-free Survival (rPFS)Time frame: Baseline until radiographic disease progression or death, whichever occurred first (approximately up to 4.7 years)
  2. Overall SurvivalTime frame: Baseline until death (up to 4.7 years)

Locations

240 sites in 40 countries. Site status is shown where the registry gives one.

  • Site not named

    Anchorage, Alaska

  • Site not named

    Tucson, Arizona

  • Site not named

    Duarte, California

  • Site not named

    Highland, California

  • Site not named

    Orange, California

  • Site not named

    Sacramento, California

  • Site not named

    San Francisco, California

  • Site not named

    Aurora, Colorado

  • Site not named

    Denver, Colorado

  • Site not named

    Deerfield Beach, Florida

  • Site not named

    Fort Myers, Florida

  • Site not named

    Jacksonville, Florida

  • Site not named

    Orlando, Florida

  • Site not named

    Port Saint Lucie, Florida

  • Site not named

    Jeffersonville, Indiana

  • Site not named

    Kansas City, Kansas

  • Site not named

    New Orleans, Louisiana

  • Site not named

    Baltimore, Maryland

  • Site not named

    Boston, Massachusetts

  • Site not named

    Lansing, Michigan

  • Site not named

    Duluth, Minnesota

  • Site not named

    Corinth, Mississippi

  • Site not named

    Columbia, Missouri

  • Site not named

    Jefferson City, Missouri

  • Site not named

    Omaha, Nebraska

  • Site not named

    Las Vegas, Nevada

  • Site not named

    Hackensack, New Jersey

  • Site not named

    East Syracuse, New York

  • Site not named

    New York, New York

  • Site not named

    Durham, North Carolina

  • Site not named

    Raleigh, North Carolina

  • Site not named

    Kettering, Ohio

  • Site not named

    Tualatin, Oregon

  • Site not named

    Hershey, Pennsylvania

  • Site not named

    Lancaster, Pennsylvania

  • Site not named

    Philadelphia, Pennsylvania

  • Site not named

    Piitsburgh, Pennsylvania

  • Site not named

    Charleston, South Carolina

  • Site not named

    Columbia, South Carolina

  • Site not named

    Chattanooga, Tennessee

Showing 40 of 240 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.